Please login to the form below

Not currently logged in
Email:
Password:

Vertex’s Orkambi receives EU green light for licence extension

Becomes first medicine to treat the underlying cause of CF in children

VertexVertex has won a green light in Europe for a licence extension that makes it the first approved medicine to treat the underlying cause of CF in children.

The US biotech’s Orkambi is now the first medicine approved in the region to treat 6-11 year olds who carry two copies of the f580del mutation.

Orkambi, a twice-daily drug, is a combination of lumacaftor and ivacaftor, designed to enhance the function of the CFTR protein once it reaches the cell surface.

Patients with CF carry little-to-no CFTR protein at the cell surface due to inheriting two defective CFTR genes and according to Vertex, there are approximately 3,400 6-11 year olds who carry two copies of the mutation.

Simon Bedson, senior vice president and international general manager at Vertex was keen to highlight the market access work the company has undertaken to help it reach patients.

He said: “The innovative long-term agreements we have reached in countries like Ireland will enable eligible children to have rapid access to Orkambi.

“Where these agreements are not in place, Vertex is committed to working with local authorities so those who could benefit from this medicine are able to do so as quickly as possible.”

Orkambi’s new approval was based on data from two phase III studies showing a statistically significant improvement in lung function among children treated with the medication compared to placebo.

Article by
Gemma Jones

11th January 2018

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics